These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23216592)

  • 1. Understanding the molecular biology of myeloma and its therapeutic implications.
    Boyd KD; Pawlyn C; Morgan GJ; Davies FE
    Expert Rev Hematol; 2012 Dec; 5(6):603-17. PubMed ID: 23216592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetics and cytogenetics of multiple myeloma: a workshop report.
    Fonseca R; Barlogie B; Bataille R; Bastard C; Bergsagel PL; Chesi M; Davies FE; Drach J; Greipp PR; Kirsch IR; Kuehl WM; Hernandez JM; Minvielle S; Pilarski LM; Shaughnessy JD; Stewart AK; Avet-Loiseau H
    Cancer Res; 2004 Feb; 64(4):1546-58. PubMed ID: 14989251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosomal and genetic abnormalities in myeloma.
    Joy Ho P
    Clin Lab Haematol; 2002 Oct; 24(5):259-69. PubMed ID: 12358886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells.
    Schmidt-Hieber M; Gutiérrez ML; Pérez-Andrés M; Paiva B; Rasillo A; Tabernero MD; Sayagués JM; Lopez A; Bárcena P; Sanchez ML; Gutiérrez NC; San Miguel JF; Orfao A
    Haematologica; 2013 Feb; 98(2):279-87. PubMed ID: 22929983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations.
    Chng WJ; Santana-Dávila R; Van Wier SA; Ahmann GJ; Jalal SM; Bergsagel PL; Chesi M; Trendle MC; Jacobus S; Blood E; Oken MM; Henderson K; Kyle RA; Gertz MA; Lacy MQ; Dispenzieri A; Greipp PR; Fonseca R
    Leukemia; 2006 May; 20(5):807-13. PubMed ID: 16511510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gender disparities in the tumor genetics and clinical outcome of multiple myeloma.
    Boyd KD; Ross FM; Chiecchio L; Dagrada G; Konn ZJ; Tapper WJ; Walker BA; Wardell CP; Gregory WM; Szubert AJ; Davies FE; Morgan GJ
    Cancer Epidemiol Biomarkers Prev; 2011 Aug; 20(8):1703-7. PubMed ID: 21680536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cytogenetic and molecular basis of multiple myeloma].
    Taniwaki M; Matsumoto Y
    Nihon Rinsho; 2007 Dec; 65(12):2179-86. PubMed ID: 18069258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetics of multiple myeloma.
    Higgins MJ; Fonseca R
    Best Pract Res Clin Haematol; 2005; 18(4):525-36. PubMed ID: 16026735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma.
    Cirrincione AM; Poos AM; Ziccheddu B; Kaddoura M; Bärtsch MA; Maclachlan K; Chojnacka M; Diamond B; John L; Reichert P; Huhn S; Blaney P; Gagler D; Rippe K; Zhang Y; Dogan A; Lesokhin AM; Davies F; Goldschmidt H; Fenk R; Weisel KC; Mai EK; Korde N; Morgan GJ; Usmani S; Landgren O; Raab MS; Weinhold N; Maura F
    Blood; 2024 Aug; 144(7):771-783. PubMed ID: 38728430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization.
    Nishida K; Tamura A; Nakazawa N; Ueda Y; Abe T; Matsuda F; Kashima K; Taniwaki M
    Blood; 1997 Jul; 90(2):526-34. PubMed ID: 9226151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and biologic implications of recurrent genomic aberrations in myeloma.
    Fonseca R; Blood E; Rue M; Harrington D; Oken MM; Kyle RA; Dewald GW; Van Ness B; Van Wier SA; Henderson KJ; Bailey RJ; Greipp PR
    Blood; 2003 Jun; 101(11):4569-75. PubMed ID: 12576322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma.
    Kaufmann H; Ackermann J; Baldia C; Nösslinger T; Wieser R; Seidl S; Sagaster V; Gisslinger H; Jäger U; Pfeilstöcker M; Zielinski C; Drach J
    Leukemia; 2004 Nov; 18(11):1879-82. PubMed ID: 15385925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic events in the pathogenesis of multiple myeloma.
    Chng WJ; Glebov O; Bergsagel PL; Kuehl WM
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):571-96. PubMed ID: 18070707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissecting karyotypic patterns in non-hyperdiploid multiple myeloma: an overview on the karyotypic evolution.
    Jimenez-Zepeda VH; Braggio E; Fonseca R
    Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):552-8. PubMed ID: 23856591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma.
    Bolli N; Li Y; Sathiaseelan V; Raine K; Jones D; Ganly P; Cocito F; Bignell G; Chapman MA; Sperling AS; Anderson KC; Avet-Loiseau H; Minvielle S; Campbell PJ; Munshi NC
    Blood Cancer J; 2016 Sep; 6(9):e467. PubMed ID: 27588520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.
    Bergsagel PL; Chesi M; Nardini E; Brents LA; Kirby SL; Kuehl WM
    Proc Natl Acad Sci U S A; 1996 Nov; 93(24):13931-6. PubMed ID: 8943038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A potential role for centrosomal deregulation within IgH translocation-positive myeloma.
    Maxwell CA; Pilarski LM
    Med Hypotheses; 2005; 65(5):915-21. PubMed ID: 16023302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic profiling of multiple myeloma: New insights and modern technologies.
    Hultcrantz M; Yellapantula V; Rustad EH
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101153. PubMed ID: 32139018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple myeloma: an update on biology and treatment.
    Ludwig H; Meran J; Zojer N
    Ann Oncol; 1999; 10 Suppl 6():31-43. PubMed ID: 10676551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biclonal origin prevails in concomitant chronic lymphocytic leukemia and multiple myeloma.
    Pantic M; Schroettner P; Pfeifer D; Rawluk J; Denz U; Schmitt-Gräff A; Veelken H; Wäsch R; Engelhardt M
    Leukemia; 2010 Apr; 24(4):885-90. PubMed ID: 20090779
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.